Amphastar reports Q4 adjusted EPS 92c, consensus 94c

Reports Q4 revenue $186.5M, consensus $188.78M. Dr. Jack Zhang, Amphastar (AMPH) President and Chief Executive Officer, commented: “We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MISTB, and we look forward to continuing to grow the brand. Furthermore, BAQSIMIB showed strong factory sales growth of 12% compared to the fourth quarter of last year. As we look ahead to 2025, we plan to continue developing and growing our proprietary pipeline.”